IL1B and rheumatoid arthritis: Whilst the role of IL-6 may be secondary compared to IL-1β for the development of pathology in the K/BxN STIA model, its inhibition leads to therapeutic benefit in experimental and human rheumatoid arthritis, as both cytokines are key therapeutic targets to stop disease progression (57).